Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2008

View Archived Issues

SVV-001 studied in experimental medulloblastoma in mice

Renovo presents results from Juvista and Zesteem trials

Rigel presents preclinical data on novel JAK2 inhibitor R-723

Qnexa meets primary endpoint in 28-week EQUATE study

Xoma provides preclinical animal data for diabetes drug XOMA-052

Valeant to acquire Dow Pharmaceutical Sciences for USD 285 million

IDMC recommends continuation of Seattle Genetics' phase IIb trial of lintuzumab in AML

Pharmacokinetic data for retigabine therapy disclosed

Nile presents results from phase Ib safety and PK study of CD-NP

Nuvelo reports encouraging results from phase I NU-206 trial in healthy volunteers

Phase III data show paliperidone's efficacy and tolerability in schizophrenia

PolyMedix announces positive phase I PMX-30063 data

ZymoGenetics reports favorable phase IIIb Recothrom results

Amylin, Lilly and Alkermes present update on DURATION clinical program for Byetta

FDA approves Pegintron/Rebetol combination in pediatric HCV patients

German regulatory authority approves CureVac's CTA to initiate phase I clinical study of CV-9103

SkyePharma and Somnus successfully complete phase I trial of SKP-1041 for sleep maintenance

Affiris initiates preclinical development of Parkinson's vaccine PD-01

Galmed successfully completes phase I trial of aramchol for fatty liver disease

Santhera completes recruitment into phase III MICONOS trial of SNT-MC17

Responses seen with afutuzumab in patients with CD20+ non-Hodgkin's lymphoma

TG-101348 appears well tolerated, decreases spleen size in myelofibrosis patients

Abraxis BioScience launches Abraxane in the European Union

Novel therapeutic agents for GERD disclosed in recent AstraZeneca patent

New antidiabetic agents disclosed in recent Merck Frosst patent

Recent Roche patent reports new agents for obesity

Rigel presents clinical data on fostamatinib disodium in B-cell NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...